S&P 500   4,561.76 (-0.13%)
DOW   35,972.66 (+0.06%)
QQQ   387.18 (-0.42%)
AAPL   190.28 (+0.17%)
MSFT   371.91 (-1.85%)
META   321.29 (-1.79%)
GOOGL   130.96 (-1.18%)
AMZN   146.20 (+0.08%)
TSLA   233.44 (-2.77%)
NVDA   464.64 (-0.65%)
NIO   7.06 (-2.89%)
BABA   72.80 (-2.78%)
AMD   119.48 (-1.39%)
T   16.64 (+0.42%)
F   10.43 (+1.66%)
MU   75.83 (-0.38%)
CGC   0.56 (+0.64%)
GE   122.59 (+0.65%)
DIS   92.02 (-0.72%)
AMC   6.92 (+4.06%)
PFE   28.99 (-4.86%)
PYPL   58.31 (+1.22%)
XOM   103.47 (+0.71%)
S&P 500   4,561.76 (-0.13%)
DOW   35,972.66 (+0.06%)
QQQ   387.18 (-0.42%)
AAPL   190.28 (+0.17%)
MSFT   371.91 (-1.85%)
META   321.29 (-1.79%)
GOOGL   130.96 (-1.18%)
AMZN   146.20 (+0.08%)
TSLA   233.44 (-2.77%)
NVDA   464.64 (-0.65%)
NIO   7.06 (-2.89%)
BABA   72.80 (-2.78%)
AMD   119.48 (-1.39%)
T   16.64 (+0.42%)
F   10.43 (+1.66%)
MU   75.83 (-0.38%)
CGC   0.56 (+0.64%)
GE   122.59 (+0.65%)
DIS   92.02 (-0.72%)
AMC   6.92 (+4.06%)
PFE   28.99 (-4.86%)
PYPL   58.31 (+1.22%)
XOM   103.47 (+0.71%)
S&P 500   4,561.76 (-0.13%)
DOW   35,972.66 (+0.06%)
QQQ   387.18 (-0.42%)
AAPL   190.28 (+0.17%)
MSFT   371.91 (-1.85%)
META   321.29 (-1.79%)
GOOGL   130.96 (-1.18%)
AMZN   146.20 (+0.08%)
TSLA   233.44 (-2.77%)
NVDA   464.64 (-0.65%)
NIO   7.06 (-2.89%)
BABA   72.80 (-2.78%)
AMD   119.48 (-1.39%)
T   16.64 (+0.42%)
F   10.43 (+1.66%)
MU   75.83 (-0.38%)
CGC   0.56 (+0.64%)
GE   122.59 (+0.65%)
DIS   92.02 (-0.72%)
AMC   6.92 (+4.06%)
PFE   28.99 (-4.86%)
PYPL   58.31 (+1.22%)
XOM   103.47 (+0.71%)
S&P 500   4,561.76 (-0.13%)
DOW   35,972.66 (+0.06%)
QQQ   387.18 (-0.42%)
AAPL   190.28 (+0.17%)
MSFT   371.91 (-1.85%)
META   321.29 (-1.79%)
GOOGL   130.96 (-1.18%)
AMZN   146.20 (+0.08%)
TSLA   233.44 (-2.77%)
NVDA   464.64 (-0.65%)
NIO   7.06 (-2.89%)
BABA   72.80 (-2.78%)
AMD   119.48 (-1.39%)
T   16.64 (+0.42%)
F   10.43 (+1.66%)
MU   75.83 (-0.38%)
CGC   0.56 (+0.64%)
GE   122.59 (+0.65%)
DIS   92.02 (-0.72%)
AMC   6.92 (+4.06%)
PFE   28.99 (-4.86%)
PYPL   58.31 (+1.22%)
XOM   103.47 (+0.71%)

Rigel Pharmaceuticals (RIGL) Stock Forecast & Price Target

$1.08
-0.06 (-5.26%)
(As of 10:46 AM ET)
Compare
Today's Range
$1.07
▼
$1.14
50-Day Range
$0.72
▼
$1.14
52-Week Range
$0.71
▼
$2.04
Volume
144,791 shs
Average Volume
2.00 million shs
Market Capitalization
$188.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Rigel Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 3 Analyst Ratings

Analysts' Consensus Price Target

$6.67
517.28% Upside
High Forecast$15.00
Average Forecast$6.67
Low Forecast$2.00
TypeCurrent Forecast
12/1/22 to 12/1/23		1 Month Ago
11/1/22 to 11/1/23		3 Months Ago
9/2/22 to 9/2/23		1 Year Ago
12/1/21 to 12/1/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$6.67$5.75$5.75$3.96
Predicted Upside517.28% Upside347.47% Upside347.47% Upside265.81% Upside
Get Rigel Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.


RIGL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RIGL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Rigel Pharmaceuticals Stock vs. The Competition

TypeRigel PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.67
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside484.80% Upside789.26% Upside4,719.15% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/2/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$15.00+1,062.78%
4/3/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingNeutral$2.00+50.38%
3/9/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$2.00 ➝ $3.00+67.60%
(Data available from 12/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












RIGL Price Target - Frequently Asked Questions

What is Rigel Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Rigel Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 2 buy ratings for RIGL. The average twelve-month price prediction for Rigel Pharmaceuticals is $6.67 with a high price target of $15.00 and a low price target of $2.00. Learn more on RIGL's analyst rating history.

Do Wall Street analysts like Rigel Pharmaceuticals more than its competitors?

Analysts like Rigel Pharmaceuticals less than other Medical companies. The consensus rating score for Rigel Pharmaceuticals is 2.67 while the average consensus rating score for medical companies is 2.67. Learn more on how RIGL compares to other companies.

Does Rigel Pharmaceuticals's stock price have much upside?

According to analysts, Rigel Pharmaceuticals's stock has a predicted upside of 353.51% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:RIGL) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -